CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

01 أبريل 2024 05:00:00 بحسب Nasdaq GlobeNewswire

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

15 فبراير 2024 13:07:00 بحسب Nasdaq GlobeNewswire

Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial

15 فبراير 2024 13:02:00 بحسب Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call

08 فبراير 2024 13:05:00 بحسب Nasdaq GlobeNewswire

Corcept Appoints Roberto Vieira as President, Oncology

29 يناير 2024 05:00:00 بحسب Nasdaq GlobeNewswire

Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program

08 يناير 2024 05:00:01 بحسب Nasdaq GlobeNewswire

Court Finds Corcept Therapeutics’ Patents Not Infringed

02 يناير 2024 05:00:00 بحسب Nasdaq GlobeNewswire

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

01 نوفمبر 2023 13:05:00 بحسب Nasdaq GlobeNewswire

Corcept Appoints Monica Tellado as President, Emerging Markets

01 نوفمبر 2023 05:00:00 بحسب Nasdaq GlobeNewswire

Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)

26 أكتوبر 2023 13:05:00 بحسب Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

25 أكتوبر 2023 13:05:00 بحسب Nasdaq GlobeNewswire

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

02 أغسطس 2023 13:05:01 بحسب Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

26 يوليو 2023 13:05:00 بحسب Nasdaq GlobeNewswire

Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)

17 يوليو 2023 13:05:00 بحسب Nasdaq GlobeNewswire

Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer

27 يونيو 2023 05:00:00 بحسب Nasdaq GlobeNewswire

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

03 مايو 2023 13:05:01 بحسب Nasdaq GlobeNewswire

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

26 أبريل 2023 13:05:01 بحسب Nasdaq GlobeNewswire

Corcept Therapeutics Announces Final Results of Tender Offer

05 أبريل 2023 13:05:00 بحسب Nasdaq GlobeNewswire

Corcept Therapeutics Announces Preliminary Results of Tender Offer

03 أبريل 2023 05:00:01 بحسب Nasdaq GlobeNewswire

Corcept Therapeutics Initiates CATALYST Clinical Trial

28 مارس 2023 13:05:00 بحسب Nasdaq GlobeNewswire